(12/28) reports, "Mylan Inc. said Tuesday that the Food and Drug
Administration approved the drugmaker's generic version of the high
blood pressure treatment eprosartan [Teveten]." The company stated that
"it is now shipping generic Teveten in strengths of 400 milligrams and
600 milligrams" and "it will have six months of marketing exclusivity."
No comments:
Post a Comment